CNSPulse
W93

REAL-WORLD IMPACT OF OLANZAPINE AND SAMIDORPHAN ON RATES OF RELAPSE AMONG YOUNG ADULTS WITH SCHIZOPHRENIA OR BIPOLAR I DISORDER

Andrew J. Cutler — Hemangi R. Panchmatia2, Alejandro G. Hughes3, Michael J. Doane2, Hara E. Oyedeji4, Rakesh Jain5 1SUNY Upstate Medical University, Neuroscience Education Institute, 2Alkermes, Inc., , 3Optum, Inc., 4Fortitude Behavioral Health, 5Texas Tech University School of MedicinePermian Basin

2026 ASCP Annual Meeting

Background

Combined olanzapine and samidorphan (OLZ/SAM) is approved for the treatment of schizophrenia and bipolar I disorder (BD-I). In real-world studies, OLZ/SAM treatment significantly reduced acute care events, which serve as proxies for relapse, in the 12 months after initiating OLZ/SAM. This claims analysis examined relapse rates (disease-related acute care events) in a subgroup of young adults, a population vulnerable to relapse.

Methods

This claims analysis used data from Komodo Healthcare Map (10/18/2020– 12/31/2023). Adults aged 18–34 years with schizophrenia or BD-I, ≥1 OLZ/SAM claim, and ≥12 months’ enrollment in medical/pharmacy benefits before and after the index date were eligible. Disease-related inpatient (IP) admissions and emergency department (ED) visits in the 12-month baseline and follow-up periods were compared; Results are presented as absolute percent changes. All-cause and mental health–related events were evaluated separately. P values ≤0.05 were considered statistically significant.

Results

Overall, 564 patients with schizophrenia and 418 with BD-I were included. For patients with schizophrenia initiating OLZ/SAM, proportions of patients with ≥1 schizophrenia-related IP admission or ED visit decreased significantly by 12.1% and 6.2% between baseline and followup, respectively (both P < 0.05). For patients with BD-I initiating OLZ/SAM, proportions of patients with ≥1 BD-I–related IP admission or ED visit decreased significantly by 18.7% and 6.7% between baseline and follow-up, respectively (both P < 0.05). In both cohorts, reductions in disease-related acute care events were numerically larger than those reported previously for the main study.

Conclusion

For young adults with schizophrenia or BD-I who are in an earlier stage of their illness, initiating OLZ/SAM may be an effective strategy for reducing relapse. This study was funded by Alkermes, Inc. Medical writing and editorial support were provided by Peloton Advantage, LLC, an OPEN Health company, and funded by Alkermes, Inc.